hotspot -WSS

hotspot

author：entertainment 2025-09-30 15:15:54 - browse：6

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： AltruBio raises $225 million to develop ulcerative colitis drug

focus

WSS

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Empower primary care with adequate payments and technology

Lawmakers grill UnitedHealth CEO on Change cyberattack

Primary care doctor shortage won't be solved by free med school tuition

Warren pushes Witty on UnitedHealth's control over physicians

The effects of a landmark ruling on DNA ownership are becoming clearer

hotspot

hotspot

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

SCOTUS to consider access to abortion pill mifepristone

After affirmative action ruling, medical educators look to 'holistic review'

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

The cancer drug shortage isn’t new — and neither are the solutions

Class action alleges UnitedHealth concealed DOJ probe

Walensky prepares to leave CDC — and Congress — behind

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

DIEP, the 'gold standard' of breast reconstruction, is under threat

GSK’s asthma push continues as drug succeeds in Phase 3 trials

leisure time

Deliver public health messages at the right time

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Radiology is caught between AI's potential and concern for patients

Warren pushes Witty on UnitedHealth's control over physicians

Radiology is caught between AI's potential and concern for patients

PBM executives asked to testify by House panel

explore

focus

knowledge

hotspot